Solid Tumor

Bicycle Therapeutics plc (NASDAQ: BCYC) has reported interim Phase I trial results for BT5528 and preliminary findings from the ongoing dose-escalation portion of the BT8009 trial. Two BT5528 monotherapy urothelial patients were dosed. Both were observed to have tumor reductions...

Prelude Therapeutics Inc (NASDAQ: PRLD) has announced data from the dose-escalation portions of Phase 1 trials of PRT543 and PRT811.  The data will be featured at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics. PRT543...

Amgen Inc (NASDAQ: AMGN) announced new combination study results from the Phase 1b CodeBreaK 101 study of Lumakras (sotorasib) for KRAS G12C-mutated cancers.  Data will be presented at the AACR-NCI-EORTC 2021 Virtual International Conference on Molecular Targets and...

Merus N.V. (NASDAQ: MRUS) has presented data on MCLA-158 and preclinical data on zenocutuzumab (Zeno) at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics. Data from Phase 1 trial of MCLA-158 (petosemtamab) in advanced head and...

GeoVax Labs Inc (NASDAQ: GOVX) entered into a license agreement with PNP Therapeutics Inc to develop and commercialize Gedeptin for solid tumors.   The transaction's detailed financial terms were not disclosed but include a combination of upfront payments,...

The Center for Drug Evaluation of China National Medical Products Administration has signed off I-Mab's (NASDAQ: IMAB) IND application to initiate a Phase 2 trial for enoblituzumab in solid tumors. The trial will evaluate enoblituzumab combined with Merck & Co Inc's...

Aprea Therapeutics Inc (NASDAQ: APRE) presented data at the European Society of Medical Oncology (ESMO) Congress 2021 from its Phase 1/2 trial in advanced solid tumors.  The trial is evaluating the safety and efficacy of eprenetapopt in combination with pembrolizumab. Related: Aprea...

Syros Pharmaceuticals Inc (NASDAQ: SYRS) announced new data from the dose-escalation portion of the Phase 1 clinical trial of SY-5609. Updated data demonstrated clinical activity in heavily pre-treated patients across multiple tumor settings. The data were presented at the European...

TCR2 Therapeutics Inc (NASDAQ: TCRR) stock dropped to a 52-week low after interim results from the ongoing Phase 1 portion of the gavo-cel Phase 1/2 trial for mesothelin-expressing solid tumors.  The data will be at the European Society for Medical Oncology (ESMO21) Congress 2021. Gavo-...

NGM Biopharmaceuticals Inc (NASDAQ: NGM) announced preliminary findings from its ongoing Phase 1a/1b dose-escalation study of NGM120 in solid tumors. Related Link: Raymond James Upgraded This Biopharma Stock And Sees 44% Upside. The data were presented at the European Society...

Athenex Inc (NASDAQ: ATNX) announced data presentation from a Phase 1 study evaluating encequidar (Oral Paclitaxel) in combination with Merck Co Inc's (NYSE: MRK) Keytruda (pembrolizumab) in advanced solid malignancies. Paclitaxel is one of the most commonly used...

Silverback Therapeutics Inc (NASDAQ: SBTX) has presented interim data from a Phase 1/1b study of SBT6050 as a monotherapy and in combination with Merck & Co Inc's (NYSE: MRK) Keytruda (pembrolizumab). Data were shared at the 2021 European Society for Medical...

Adaptimmune Therapeutics plc (NASDAQ: ADAP) has announced updated data from its Phase 1 SURPASS trial in multiple solid tumors evaluating ADP-A2M4CD8. ADP-A2M4CD8 is a next-generation T-cell therapy engineered to target MAGE-A4 positive tumors and to express a CD8α co-receptor...

Werewolf Therapeutics Inc (NASDAQ: HOWL) has entered into a clinical trial collaboration and supply agreement with Merck & Co Inc (NYSE: MRK) to evaluate WTX-124 in combination with Keytruda (pembrolizumab). WTX-124 is a systemically delivered, conditionally activated...

The FDA has approved a second indication for GlaxoSmithKline plc's (NYSE: GSK) Jemperli (dostarlimab-gxly). The approval comes for adult patients with mismatch repair deficient (dMMR) recurrent or advanced solid tumors that have progressed on or following prior treatment...